ABOUT POLYPLUS
Polyplus SA is the leading biotechnology company that supports Gene and Cell therapy, biologics manufacturing and life science research with innovative nucleic acid transfection solutions. Polyplus strengths are 20 years of experience in manufacturing transfection solutions with tailored scientific and regulatory support to accelerate research. Based in the Science Park close to Strasbourg (France), Polyplus offers an extensive and growing range of transfection reagents available worldwide.
PRODUCTS
Plasmid DNA manufacturing using a unique process for Research, HQ and GMP grades
Benefits
- Purity- High purity plasmids with very low endotoxin level (< 2EU/mg)
- Robust- Unique scalable proprietary process allowing plasmid production from 50mg to 20g in Research, HQ & GMP grades
- Time-Saving- Between 4 and 7 weeks for Research Grade and 3 months for GMP grade
- Flexible- Manufacturing process compatible with all types of plasmids (from 2 to more than 20 kb, plasmids for LV, AAV, mRNA)
LipidBrick® IM21.7c
- Efficient: Modulates LNP properties to adapt the biodistribution depending on the therapeutic purpose
- Secure: Use a unique lipid structure protected by an independent patent owned by Polyplus®
- Accelerate your project: in vitro and in vivo proof of concept have been successfully performed
FectoVIR®-LV
Lentiviral vectors are recognized to be the carrier of choice for allogenic or autologous cell therapies (such as CAR-T) because of its capacity to permanently integrate viral genome into host cell DNA. To produce those vectors, cell therapy producers generally use a transient transfection system that is scaled-up during process development phases. FectoVIR®-LV is the next generation of transfection reagent, free of animal component, designed to improve LV productivity in HEK-293 cell systems. FectoVIR-LV is made for large scale manufacturing with reduction of the complexation volume and increased complex stability. The benefits that FectoVIR-LV bring allow to increase number of doses produced per batch to treat more patient, while decreasing manufacturing costs.
LipidBrick® IM21.7c
- Efficient: Modulates LNP properties to adapt the biodistribution depending on the therapeutic purpose
- Secure: Use a unique lipid structure protected by an independent patent owned by Polyplus®
- Accelerate your project: in vitro and in vivo proof of concept have been successfully performed
Take your gene expression to the next level by switching to mRNA!
Primary cells, neurons, suspension cells and various cancer cell lines are especially challenging to transfect. jetMESSENGER® gives high transfection efficiency in all of these usually difficult to transfect cells, by allowing highly efficient mRNA transfection.
mRNA transfection is as easy as DNA transfection, with the advantage that mRNA does not need to reach the cell nucleus for expression nor require cell division for efficient gene expression. Hence, cells that are slow dividing or that have developed specific mechanisms to protect their genome can finally be used for gene expression.
Unravel the full potential of your cells by switching to mRNA transfection.
PEIpro® transfection reagent is the leading chemical-based DNA transfection reagent that offers flexibility and scalability to develop a robust and sustainable Process Development for viral vector production.
Efficient: 100% mRNA encapsulation leading to comparable LNP delivery results
in vivo-jetRNA®+ is the reagent of choice to deliver mRNA to various organs. This is attributable to its intrinsic properties: in vivo-jetRNA®+ protects its payload against ubiquitous endonucleases, prevent non-specific interactions with proteins and promote efficient cell entry.
Ace your DNA transfection in the cell model you need!
As Transfection Experts, we know that it is essential for biologists to work with physiologically relevant cell models. For gene expression studies, transfection is the preferred technique to introduce a gene of interest in a given cell model, due to its cost-effectiveness and simplicity-of-use in comparison to physical techniques (e.g. micro-injection, electroporation)
FectoVIR®-AAV GMP ticks all the boxes to make each AAV-based gene therapy a success.
CONTACT INFORMATION
Polyplus
1251 Ave of the Americas 3rd Fl
New YorK, NY 10020
UNITED STATES
BROCHURES AND DATASHEETS
PODCASTS & WEBINARS
FEATURED ARTICLES
-
![iStock-823447656-vector-viral-lab-AAV-cell-development]( "Improve Your AAV Manufacturing Process")
Meet the growing demand for AAV-based gene therapies using design-of-experiment and fit-for-purpose plasmids and transfection reagents.
-
![GettyImages-1226044009-lab-virus-dna-research-cleanroom]( "Transfection Reagents For Scalable Virus Production")
Why is this transfection reagent often chosen for virus production runs in the most adherent and suspension cell culture systems and what are it's benefits?
-
![Methodology Best Practice GettyImages-624652966]( "Successful Scaling Of Suspension-Based Viral Vector Production")
Explore this discussion amongst experts about how to develop robust, scalable, and cost-effective processes that yield high titers of high-quality viral vectors.
-
![Stem cells GettyImages-1372020543]( "Efficiency Of A Transfection Reagent In Hard-To-Transfect Stem Cells")
Discover how our transfection reagent demonstrates robust, non-toxic and efficient gene expression delivery in hard-to-transfect primary hMSCs, mESCs and induced pluripotent stem cells.
-
![scientist iStock-1166567091]( "mRNA Transfection Reagent Enhances Non-Viral Gene Delivery To Stem Cells")
Researchers demonstrate a delivery mechanism that is a simple and ready-to-use transfection reagent that leads to outstanding transfection efficiencies in known hard-to-transfect stem cells.
-
![GettyImages-530438981-lab-manufacturing]( "Commercializing ATMP Manufacturing Processes")
Improving this one aspect of viral vector manufacturing can help enable scalable production of high-quality vectors with acceptable costs and timelines for advanced therapy medicinal products (ATMPs).
-
![Pharma bioprocess quality GettyImages-1138461306]( "Zoom On The Importance Of Quality For Viral Vector Manufacturing Optimization")
Industry experts offer advice on the use of GMP raw materials for viral vector manufacturing along with the key points of evolution relating to regulatory guidance and requirements for viral vector production.
-
![Scientists laboratory GettyImages-640071044]( "Differences, Challenges And Best Practices For Manufacturing Of Biologics Under GMP Compliance")
A regulatory affairs specialist discusses best practices and challenges for manufacturing biologics under GMPs and reviews details around the EU’s revision to Annex 1.
-
![GettyImages-532549174-lab-bioreactor-development]( "Optimization Of AAV Production For High-Yielding And Scalable GMP Processes")
By leveraging a standardized, scalable platform approach for viral vector manufacturing, including the transient transfection step, timelines can be accelerated to bring next-generation therapies to market.
-
![Scientist lab cell and gene dna GettyImages-1305079941]( "Ancillary Material Regulatory Digest For ATMPs")
It’s worth carefully assessing the eligibility of an AM before as early as possible before entering clinical testing as it will result in a significant gain of time and money.
-
![iStock-1310024666-mrna-dna]( "Fine-Tuning Transient Transfection Conditions Is A Prerequisite For Optimal Upstream AAV Manufacturing")
Read how optimizing the transfection step during upstream process development leverages tremendous benefits on overall costs, robustness and scalability of an AAV production platform.
-
![Cell & Gene iStock-526543362]( "Improving Expression And Purification Of mAb")
To achieve high transient protein yields, TGE is dependent on an efficient transfection method. We review a system for optimal protein production in several commercially available suspension CHO cell lines.
-
![iStock-1155553590-syringe-glove-doctor-vaccine-medicine]( "Transfection Toolbox For Spike Protein Vaccine Strategies")
We review 4 main strategies for current COVID-19 vaccines currently in development: virus-based vaccines, nucleic acid-based vaccines, protein-based vaccines and viral vector vaccines.
-
![Genomic Laboratory Services]( "Expression Of Recombinant Proteins")
The expression of recombinant proteins has evolved to allow the development of innovative diagnostic and therapeutic applications.
-
![iStock-1166057429-viral-vector-vaccine-cell]( "Viral Vectors For Gene Therapy In A Nutshell: AAVs, Lentivirus, Adenovirus And Retrovirus")
We review the four main types of viral vectors utilized for gene therapy applications and chemical transfection reagents options for efficient production of viral vectors at all scales.
-
![mRNA iStock-1295693748]( "Transfection Solutions For Highly Reliable And Effective Gene Silencing With siRNA And Co.")
We discuss the process of transfection and highlight two highly effective vectors for both in vitro and in vivo gene therapy applications.
-
![iStock-601373580-lab-dropper-cell]( "Lentiviral Transfection For Advancing Cell-Based Gene Therapy")
Explore how lentiviral vectors can be used across a range of clinically relevant cell-based gene therapies and highlight a transfection reagent has become the gold standard for efficient, reproducible and cost-effective lentivirus manufacturing.
-
![Human cell GettyImages-1055110266]( "The Importance Of Raw Materials In Viral Vector Manufacturing")
It is extremely important to confirm the identity, purity, and quality of raw materials prior to starting the viral vector manufacturing to ensure patient safety is being considered and safeguarded from the start of the manufacturing process.
-
![Gene Therapy]( "Manufacturing A Gene Therapy With Patient Safety In Mind")
To monitor and guarantee their safety, advanced medicines need to follow strict and specific cGMP regulations, similarly to what applies to standard pharmaceuticals.
-
![iStock-823447656-vector-viral-lab-AAV-cell-development]( "AAV Vector Manufacturing: Transfection Matters")
Optimizing the transfection process and its efficiency is paramount to boosting vector titers during scale-up and manufacturing of AAV vectors with new generation transfection reagent addressing large scale manufacturing constraints.
